Betaserk

General characteristics. Structure:

Active agent: betagistina dihydrochloride of 24 mg

Excipients: MKTs; Mannitolum; citric acid monohydrate; silicon dioxide colloid; talc.

Pharmacological properties:

Pharmacodynamics. Influences, mainly, histamine H1-and H3 receptors of an inner ear and vestibular nuclei of TsNS.

By direct agonistic impact on H1 receptors of vessels of an inner ear, and also indirectly through impact on H3 receptors improves microcirculation and permeability of capillaries, normalizes endolymph pressure in a labyrinth and a snail, increases a blood stream in a basilar artery. Has the expressed central effect, normalizes neyronalny transmission in neurons of vestibular nuclei at the level of a brain trunk. Reduces the frequency and intensity of dizzinesses, reduces a sonitus, improves hearing in case of its decrease.

Pharmacokinetics. It is quickly absorbed, slightly contacts proteins of plasma. Cmax in a blood plasma is reached in 3 h, T1/2 — 3–4 h. It is almost completely removed by kidneys in the form of a metabolite (2-peridiluksusny acid) during 24 h.

Indications to use:

- vestibular dizzinesses of various origin (treatment and prevention);
- the syndromes including dizziness and a headache, a sonitus, the progressing hearing impairment, nausea and vomiting;
- Menyer's disease/syndrome.

Route of administration and doses:

Inside, during food. According to 1 tab. 2 times a day. Duration of administration of drug is selected individually (prolonged treatment).

Improvement is usually noted already at the beginning of therapy, the stable therapeutic effect is reached after 2 weeks of treatment and can increase within several months of treatment.

Features of use:

It is necessary to be careful at treatment of patients with a peptic ulcer of a GIT (including in the anamnesis), a pheochromocytoma and bronchial asthma (during treatment regular observation is necessary).

Does not possess sedative action and does not influence ability to drive the car or to work at machines and mechanisms.

Side effects:

Disorders of a GIT. It was seldom or never reported about emergence of reactions of hypersensitivity from integuments (rash, an itch, urticaria); Quincke's edema.

Interaction with other medicines:

Cases of interaction or incompatibility with other HP are unknown.

Contraindications:

Hypersensitivity to drug components.

Use at pregnancy and feeding by a breast
There are not enough data for assessment of influence of drug during pregnancy and breastfeeding.

Overdose:

Symptoms: nausea, vomiting, were available messages on emergence of spasms at reception of a dose of 728 mg.

Treatment: symptomatic.

Storage conditions:

In the dry place, at a temperature not above 25 °C.
To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

In the blister of 20 pieces; in a pack of cardboard 1, 2, 3 or 5 blisters or in the blister of 25 pieces; in a pack cardboard 1, 2 or 4 blisters.